Editas Medicine
EDITEditas Medicine is a clinical-stage biotechnology company focused on developing transformative genomic medicines using CRISPR-based gene editing technology.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 1 week)Competitors
By market cap
Profile
Editas Medicine is a clinical-stage biotechnology company focused on developing transformative genomic medicines using CRISPR-based gene editing technology. The company leverages a proprietary platform encompassing Cas9 and Cas12a enzymes to perform in vivo functional upregulation, aiming to treat serious genetic diseases by increasing normal gene expression. Their core strategy involves a 'plug and play' lipid nanoparticle delivery system to target specific tissues such as the liver and hematopoietic stem cells.
Editas is a pioneer in the CRISPR space, uniquely holding a platform that includes both Cas9 and Cas12a systems with foundational intellectual property.
Questions, answered.
- What is Editas Medicine's market cap?
- Editas Medicine (EDIT) has a market capitalization of $411.3M and trades on NASDAQ.
- Who are Editas Medicine's competitors?
- Editas Medicine's key competitors include Vertex Pharmaceuticals Incorporated, Precision BioSciences, Inc. Common Stock, CRISPR Therapeutics AG, and others. These companies compete in similar markets and product categories.
- Who does Editas Medicine partner with?
- Editas Medicine's notable partners include Bristol Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Immatics, and others.
- Where is Editas Medicine headquartered?
- Editas Medicine is headquartered in United States of America and employs approximately 226 people. It has been publicly traded since 2016.